NCT03435796 2026-03-04
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Celgene
Phase 2/3 Recruiting
Clinical Trials
5 trialsNCT07005102 2026-01-23
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie
Phase 2/3 Recruiting
NCT06697301 2025-11-12
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Eikon Therapeutics
Phase 2/3 Recruiting
NCT05749302 2024-03-29
Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3 Recruiting
NCT05623267 2023-08-07
SURPASS
Sun Yat-sen University
Phase 2/3 Recruiting